Lion gets exclusive license from NIH to develop TIL Therapy for metastatic melanoma
The exclusive license was received through an amendment to Lion’s previously granted, non-exclusive, worldwide license to certain NIH issued and pending patent applications for the use of TIL
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.